BiotechTube

tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low Back Pain

Conditions

Low Back Pain

Trial Timeline

Dec 1, 2007 → May 1, 2008

NCT ID
NCT00594516

About tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)

tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR) is a phase 3 stage product being developed by Johnson & Johnson for Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00594516. Target conditions include Low Back Pain.

What happened to similar drugs?

6 of 20 similar drugs in Low Back Pain were approved

Approved (6) Terminated (4) Active (13)
🔄DuloxetineShionogiPhase 3
🔄Duloxetine + PlaceboShionogiPhase 3
🔄Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
🔄EperisoneEisaiPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00594516Phase 3Completed

Competing Products

20 competing products in Low Back Pain

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
AZD1940 + MidazolamAstraZenecaPhase 1
29
MK-0663B + DOLOCAM PLUS® + Acetaminophen 500 mgMerckPhase 3
32